In study COALL-85 in high risk patients slow vs rapid rotational treatment was randomized. In study COALL-92 initial response to daunorubicin (DNR) as a 1-h vs 24-h infusion and its prognostic value was investigated. Furthermore, 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) were randomized in maintenance treatment. In total, 1191 eligible patients were enrolled. Induction treatment without ASP has been shown to be as effective and less hazardous than the former four-drug induction. CNS control could be obtained in most without cranial irradiation (CNS relapse-free survival Ͼ95%). The leukemic cell kill with a 24-h DNR infusion was equivalent to that of a 1-h infusion. DNR response was of less prognostic significance than prednisone response. The rapid rotation regimen failed to improve outcome as well as 6-TG in maintenance treatment. However, intensification of systemic treatment resulted in an increase in overall event-free survival (EFS) to approximately 80% which is comparable to other groups. Leukemia (2000) 14, 2234-2239.
Introduction
In 1980 the COALL Study Group, part of the German Society of Pediatric Oncology and Hematology, was founded. Objective of the first multicenter trial, COALL-80, was to reduce treatment-related morbidity and mortality in induction without loss of efficacy. The regimen corresponded to the very effective BFM-76/79 protocol. However, ASP was omitted from the four-drug induction and interposed between induction and CNS treatment.
This report gives an overview of the overall EFS-and CNSrelated disease-free survival in the consecutive studies COALL 82, 85, 89 and 92. Treatment results according to initial findings and according to risk groups (NCI/Rome Criteria) and immunological lineage are presented.
Materials and methods
During 1982 and 1997, four trials for the treatment of childhood ALL were completed by the COALL Study Group. After informed consent 1191 patients with newly diagnosed precur- sor B-ALL or T-ALL were entered into the protocols from 24 children's hospitals all over Germany. In the protocols patients aged 18 years or younger were eligible, however, in trials COALL-89 and COALL-92 infants were treated according to a different regimen. Table 1A and B show summaries of the different treatment schedules. Detailed information of the COALL studies has been given previously. [1] [2] [3] [4] [5] In study COALL-82 (1982 COALL-82 ( -1985 , for the subgroup of patients defined as low risk by an initial WBC Ͻ25 × 10 9 /l and immunological subtype common-ALL a reduction of treatment intensity was performed. During intensive phase, consisting in COALL-80 of cyclophosphamide (CYC), three blocks of cytarabine (ARA-C) and 6-MP, CYC was replaced by intermediatedose methotrexate (MTX) and no reinduction therapy was given. Furthermore, in low risk patients with initial WBC Ͻ3 × 10 9 /l cranial irradiation was replaced by six doses of MTX intrathecally (i.th.) whereas in all other patients CNS irradiation at risk-and age-adapted dose (12-18 Gy) was given without MTX i.th. In high risk patients high-dose MTX was added to CYC in intensive phase and reinduction with four times vincristine (VCR) and adriamycin was intensified by teniposide, ARA-C and 6-TG. All high risk patients received CNS irradiation (16-24 Gy). In this and all consecutive studies irradiation was limited to the head. In the studies COALL-82 and COALL-85, only in the case of initial CNS involvement was spinal irradiation performed.
Treatment
On the study 143 patients were enrolled of whom 10 were ineligible because of pre-treatment (other than VCR, DNR, prednisone (PRED) and/or longer than 2 weeks) or mature B-ALL. Sixty-six children (49%) were treated according to the low risk protocol, approximately one-quarter of these low risk patients without cranial irradiation.
In the consecutive study, COALL-85 (1985 COALL-85 ( -1989 , age was included as an additional prognostic factor: patients aged 10 years and older at diagnosis were treated according to the high risk protocol. In this risk group slow vs rapid rotation of six non-crossresistant drug combinations with 12 different agents was randomized during intensive phase. Systemic therapy for low risk patients was as in study COALL-82. CNS irradiation again was combined with MTX i.th. All low risk patients (defined as common-ALL or pre-B-ALL, aged 1 to Ͻ10 years, WBC Ͻ25 × 10 9 /l, absence of t(4;11) or t(9;22) and complete remission after induction therapy) with initial WBC Ͻ5 × 10 9 /l were excluded from irradiation. Into this study 319 patients were entered; 14 had to be excluded because of pre-treatment or incorrect diagnosis. According to their presenting features 169 patients (55%) belonged to the high risk group. Eighty-two percent of all patients underwent cranial irradiation (low risk: 12-18 Gy, high risk: 16-24 Gy). In protocol COALL-89 (1989-1992) definition of risk groups and therapy for high risk patients was the same as in COALL-85. However, in April 1990 randomization was stopped due to inferior results in the subset of patients with WBC Ͼ100 × 10 9 /l. Subsequently, the slow rotation branch was given to all children.
Treatment of the low risk group was newly intensified by adding three drug combinations from the high risk protocol to the intensive phase and by reintroduction of reinduction. The initial WBC as criterion for CNS irradiation was increased to 10 × 10 9 /l, additionally, irradiation dose was diminished to 12 Gy for patients aged 1-2 years, respectively to 18 Gy for older children.
Because of the poor results in study COALL-85 children aged Ͻ1 year from then were treated according to a different schedule based on the regimen for mature B lineage nonHodgkin lymphomas.
Two hundred and twenty-one children were registered on the study. Six were ineligible because of pre-treatment and 10 children were enrolled in the infant protocol. From the remaining 205 patients, 112 had low risk features at presentation. The percentage of non-irradiated patients was approximately 40%.
On study COALL-92 (1992 COALL-92 ( -1997 , that closely followed the previous protocol regarding intensive phase treatment, 578 patients were enrolled. The number of ineligible patients was 40 -many Russian children who were treated in German hosLeukemia pitals during these years were pre-treated. According to the infant protocol, 17 children younger than 1 year at diagnosis were treated. Of the remaining 521 patients, the first 178 were stratified into WBC Ͻ25 × 10 9 /l vs у25 × 10 9 /l and then randomized to receive in a therapeutic window a single dose of 36 mg/m 2 DNR either as a 1-h (85 patients) or 24-h infusion (93 patients) prior to any treatment to examine the in vivo leukemic cell kill of DNR and its prognostic value. All subsequent DNR doses were given as 1-h infusion. In maintenance treatment 6-MP and 6-TG were randomized. CNS irradiation was only administered in high risk patients. Since April 1994 patients with common-or pre-B-ALL and WBC Ͻ50 × 10 9 /l were excluded from irradiation. Therefore, only approximately one third of all patients still underwent cranial irradiation.
Statistical analysis
Duration of event-free survival (EFS) was defined as the time from achievement of complete remission until the date of failure (death, relapse, second malignancy and induction failures such as death during induction therapy or failure to achieve complete remission by day 56 (non-response)). Early death and non-response were considered failures at time zero. EFS rate and probability of CNS relapse-free survival were estimated as intent to treat by using the Kaplan-Meier method and log-rank tests were used to evaluate differences between the EFS in patient groups. 6, 7 Patients without failure were censored at the day of last follow-up on 1 September 1999.
An isolated CNS relapse was defined as CNS relapse without evidence of involvement at other sites. A CNS relapse was defined as isolated CNS relapse or a CNS relapse in combination with another type of relapse. For estimation of isolated CNS relapse-free survival or CNS relapse-free survival patients who failed during induction were excluded. Patients experiencing other types of event prior to isolated CNS respectively any CNS relapse were censored at the day of event.
Status of patients is monitored annually by a questionnaire sent from the study head office in Hamburg, Germany to the physicians in attendance. Patients are stated as lost to followup when they could not be contacted for more than 2 years. At 1 September 1999 in studies COALL-82, -85, -89, -92 approximately 9%, 10%, 12% and 2% respectively of patients were lost to follow-up. During intensive treatment no patient has been lost to follow-up, during maintenance treatment one each in COALL-82 and COALL-89, two in COALL-92.
Results

Treatment outcome according to protocols COALL-82:
Of the 133 patients enrolled, two (1.5%) failed to achieve complete remission due to early death (one) or non-response (one). The overall EFS at 5 years was 55.5 ± 4.2% s.e. (Figure 1 ). The median follow-up time for patients at risk was 16.2 years (range 14.4-17.6). CNS relapsefree survival was 86.5 ± 3.1% (Figure 2 ), isolated CNS relapsefree survival 88.4 ± 2.9% at 5 years ( Figure 3 ).
COALL-85:
Of 305 patients, 301 (98.7%) attained com- plete remission (one early death, three non-responses). At 5 years overall EFS was 68.5 ± 2.6%. The median observation period of event-free patients was 12.7 years (range 10.5-14.6). At 5 years CNS relapse-free survival was 94.6 ± 1.3%, isolated CNS relapse-free survival 97.2 ± 0.9%. Rapid rotation failed to improve the outcome in the total high risk group. The overall EFS for this subgroup was 66.9 ± 5.1% whereas in patients on the slow rotation regimen it was 76.1 ± 4.8% after 5 years (P = 0.29). In B-lineage ALL rapid rotation even appeared to impair results (61.5 ± 6.5 vs 77.7 ± 87.8%, P = 0.15).
COALL-89:
Two hundred and nine (97.2%) of 225 eligible patients achieved complete remission. Reasons for induction failures were one early death and five non-responses. EFS at 5 years was 78.5 ± 2.7 for the total group (including infants), CNS relapse-free survival 96.4 ± 1.3% and isolated CNS relapse-free survival 99.4 ± 0.4%. The median follow-up time of patients remaining event-free was 9.3 years (range 7.6-10.7).
COALL-92:
Complete remission was achieved in 531 (98.7%) of 538 enrolled patients (two early deaths, five nonresponses). Patients on risk had a median observation time of 4.9 years (range 2.1-7.6). At 5 years the overall EFS rate was 76.9 ± 1.9%. The 5-year CNS relapse-free survival was 95.8 ± 0.9%, the isolated relapse-free survival 97.3 ± 0.7%. Maintenance treatment with 6-TG had no impact on outcome for either high risk or low risk groups nor for B-lineage or T-lineage ALL.
Treatment results according to presenting features (Tables 2-5)
Throughout all COALL studies male sex was associated with a poorer outcome. However, results were not statistically significant. Compared to patients aged 1 to 9 years outcome of older children was significantly worse in studies COALL-82 (P = 0.02), COALL-89 (P = 0.001) and COALL-92 (P = 0.01) whereas this factor did not influence the results in study COALL-85. Children younger than 1 year at diagnosis fared statistically worse throughout all studies. In the early studies COALL-82 and COALL-85, no patient of this group remained event-free. In COALL-89 and COALL-92, infants profited from .2) 58.3 ± 13.4 50.0 ± 13.5 50.0 ± 13.5 high risk the different treatment but still had a significantly poorer outcome (EFS 40-44%).
Leukemia
An initial WBC у100 × 10 9 /l in trial COALL-85 had no effect on EFS in comparison to the subsequent trials COALL-89 (P = 0.002) and COALL-92 (P = 0.001). Except for study COALL-89 the prognosis of patients with T-ALL was not significantly different from B-lineage ALL although only 24% of all patients with T-ALL were standard risk cases according to the NCI/Rome criteria (aged 1 to 9 years, WBC Ͻ50 × 10 9 /l). The percentage of standard risk patients in B-lineage ALL was approximately 70%.
Discussion
Response rates were approximately 98% in all trials and no thromboembolic events occurred in 1191 eligible patients during induction therapy. Mortality before achievement of complete remission was low and mostly due to infections. Therefore, the COALL studies show that induction therapy without ASP is as effective as and less hazardous than the former four-drug induction. 8 Another objective of the consecutive COALL studies was the reduction of CNS irradiation. In the first trial, COALL-80, 3.8% patients developed malignant brain tumors after irradiation. Therefore, the initial WBC as criterion for CNS irradiation was gradually increased. For the majority of patients, excluding T-ALL and patients with a WBC у50 × 10 9 /l who still received irradiation, treatment with intermediate-dose MTX and multiple doses of MTX i.th. was shown to be as effective as irradiation for control of CNS disease.
Simultaneous reduction of systemic treatment and i.th. CNS therapy, however, caused a remarkably worse outcome in CNS control in protocol COALL-82, in which cranial irradiation was applied without MTX i.th. and reinduction was omitted in low risk patients.
An improvement of the EFS for high risk patients was achieved by the treatment intensification in the COALL-85 protocol, but rapid rotation during intensive therapy had no favorable impact on treatment outcome. 4 In patients with an initial WBC у100 × 10 9 /l this regimen appeared to be even less effective. In low risk patients with a 5-year EFS of only 62% a retrospective analysis showed the importance of the timing of leucovorin rescue. 9 In a subgroup of patients leukovorin rescue had been given at 38-42 h instead of 48 h. EFS for the 'early rescue' group with 28% was significantly worse than for the 'late rescue' group (69%).
In study COALL-89, further intensification in intensive phase and reintroduction of reinduction benefited the low risk group whose EFS at 5 years rose to 80%.
The use of 6-TG during maintenance treatment of protocol COALL-92 was not superior to 6-MP (5-year EFS 80.1 ± 2.9 vs 82.8 ± 2.6). 6-TG differs in its hematological toxicity and is therefore more complicated to handle than the standard therapy with 6-MP. 10, 11 The results of our DNR response study showed that in children with ALL a 24-h infusion of DNR has the same cytotoxic effect for leukemic cells as a 1-h infusion without increase of toxicity. This offers the possibility of using a prolonged appli- cation of anthracyclines with equal efficacy and hopefully less cardiotoxicity. Response to DNR within the first week is of prognostic significance. 12 However, it does not discriminate Leukemia as well as initial response to PRED as has been shown by the ALL-BFM study. 13 In the COALL studies T-ALL had a similar prognosis as Bprecursor ALL except in COALL-89, in which only a small number of patients was entered. As expected, patients with a high WBC had more relapses. Children with age у10 years who were included in the high risk group since study COALL-85 profited from this intensified high risk treatment.
